When a child under 18 experiences a relapse of Anti-NMDA-receptor encephalitis, the clinical situation calls for a defined, evidence-based treatment pathway. The full structured protocol is available below.
This protocol applies to children (age <18 years) with a confirmed relapse of NMDA receptor antibody encephalitis — defined as the return of previously resolved symptoms and signs, or the appearance of new symptoms or signs associated with a change in function, after a period of stability or improvement of at least one month, not attributable to adverse drug reactions or intercurrent illness.
In this setting, management may involve escalation to a second-line immunotherapy agent — with the choice of agent informed by what was used in the prior course. The complete protocol specifies which agents apply, when, and under what conditions.
The target is adequate clinical improvement, evaluated approximately 1–3 months after second-line treatment is initiated.
Return of previous resolved symptoms and signs, or appearance of new symptoms or signs, associated with change in function, lasting more than 1 wk (or shorter if associated with change in safety), that cannot be explained by adverse reactions to current medications or intercurrent illness, after a period of stability or improvement of at least 1 mo.
Although generally only one second-line treatment is used, another second-line treatment (i.e., cyclophosphamide [CYC], if RTX was used first, or vice versa) can be used in patients who fail to improve after relapse.
View source ↗